Literature DB >> 25310459

Persistent epicardial adipose tissue accumulation is associated with coronary plaque vulnerability and future acute coronary syndrome in non-obese subjects with coronary artery disease.

Koki Nakanishi1, Shota Fukuda2, Atsushi Tanaka3, Kenichiro Otsuka4, Satoshi Jissho2, Haruyuki Taguchi2, Junichi Yoshikawa5, Kenei Shimada4.   

Abstract

Objective. Epicardial adipose tissue (EAT) is recognized as a novel risk factor for coronary artery disease (CAD), and its contribution is thought to be stronger in non-obese patients than in obese patients. However, the prognostic impact of the progression of EAT accumulation after comprehensive management for atherosclerotic risk factors remains unclear. This study aimed to investigate whether an increase of the EAT volume during follow-up predicts future acute coronary syndrome (ACS) events in non-obese CAD patients. Methods. This study consisted of 517 non-obese CAD patients (368 men; age, 66 ± 10 years) who underwent serial multidetector computed tomography (MDCT) examinations to evaluate coronary atherosclerosis progression. The MDCT examination was used to assess the severity of stenosis, plaque characteristics, and EAT volume. All patients received comprehensive management to reduce CAD risk factors after the first MDCT examination. The MDCT examination was repeated at 6-24 months, and patients were followed-up for more than 1 year or until the occurrence of ACS events. Results. Of 517 patients, 159 (31%) patients were classified into increase of EAT volume during follow-up, 91 (18%) into decrease of EAT volume during follow-up, and 267 (51%) patients into constant of EAT volume during follow-up. The prevalence of obstructive plaques and MDCT-derived vulnerable features of coronary plaques were significantly elevated in patients with increase of EAT volume during follow-up. In contrast, no significant changes were observed in the other 2 groups. During the follow-up period of 4.1 ± 1.8 years (median 4.4 years) after the second MDCT examination, ACS occurred in 43 (8.3%) patients. Multivariate Cox regression analysis showed that the presence of low-attenuation plaque (hazard ratio [HR]; 1.78, p = 0.04) and napkin-ring sign (HR; 3.74, p < 0.001) at second MDCT examination, and changes of EAT volume per 10 ml (HR; 1.34, p = 0.004) were associated with future ACS events. Conclusion. Patients with increase of EAT volume during follow-up despite comprehensive management for CAD risks had an increased prevalence of obstructive plaques and plaques with high-risk features, which could be associated with unfavorable ACS outcomes in non-obese CAD patients.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Epicardial adipose tissue; Multidetector computed tomography

Mesh:

Year:  2014        PMID: 25310459     DOI: 10.1016/j.atherosclerosis.2014.09.015

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

Review 1.  Local and systemic effects of the multifaceted epicardial adipose tissue depot.

Authors:  Gianluca Iacobellis
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

Review 2.  The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles.

Authors:  Alexios S Antonopoulos; Charalambos Antoniades
Journal:  J Physiol       Date:  2017-03-13       Impact factor: 5.182

3.  Epicardial adipose tissue is associated with high-risk plaque feature progression in non-culprit lesions.

Authors:  Yahang Tan; Jia Zhou; Ying Zhou; Xiaobo Yang; Jing Wang; Yundai Chen
Journal:  Int J Cardiovasc Imaging       Date:  2017-05-26       Impact factor: 2.357

4.  Pericoronary adipose tissue ratio is a stronger associated factor of plaque vulnerability than epicardial adipose tissue on coronary computed tomography angiography.

Authors:  Ryo Okubo; Rine Nakanishi; Mikihito Toda; Daiga Saito; Ippei Watanabe; Takayuki Yabe; Hideo Amano; Tatsushi Hirai; Takanori Ikeda
Journal:  Heart Vessels       Date:  2017-02-22       Impact factor: 2.037

Review 5.  The Role of Epicardial Fat in Pericardial Diseases.

Authors:  George Lazaros; Alexios Antonopoulos; Charalambos Antoniades; Dimitris Tousoulis
Journal:  Curr Cardiol Rep       Date:  2018-04-19       Impact factor: 2.931

6.  Relationship between epicardial fat and quantitative coronary artery plaque progression: insights from computer tomography coronary angiography.

Authors:  Peter J Psaltis; Andrew H Talman; Kiran Munnur; James D Cameron; Brian S H Ko; Ian T Meredith; Sujith K Seneviratne; Dennis T L Wong
Journal:  Int J Cardiovasc Imaging       Date:  2015-09-03       Impact factor: 2.357

Review 7.  Association of Epicardial Adipose Tissue and High-Risk Plaque Characteristics: A Systematic Review and Meta-Analysis.

Authors:  Nitesh Nerlekar; Adam J Brown; Rahul G Muthalaly; Andrew Talman; Thushan Hettige; James D Cameron; Dennis T L Wong
Journal:  J Am Heart Assoc       Date:  2017-08-23       Impact factor: 5.501

Review 8.  Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF).

Authors:  Emmanuel Eroume A Egom
Journal:  Front Physiol       Date:  2021-05-21       Impact factor: 4.566

9.  Epicardial Adipose Tissue Is Associated with Plaque Burden and Composition and Provides Incremental Value for the Prediction of Cardiac Outcome. A Clinical Cardiac Computed Tomography Angiography Study.

Authors:  Gitsios Gitsioudis; Christina Schmahl; Anna Missiou; Andreas Voss; Alena Schüssler; Hassan Abdel-Aty; Sebastian J Buss; Dirk Mueller; Mani Vembar; Mark Bryant; Hans-Ulrich Kauczor; Evangelos Giannitsis; Hugo A Katus; Grigorios Korosoglou
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

Review 10.  Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.

Authors:  Nicholas J Montarello; Mau T Nguyen; Dennis T L Wong; Stephen J Nicholls; Peter J Psaltis
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.